Literature DB >> 27467929

Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1.

Erika Vacchelli1, Yuting Ma2, Elisa E Baracco3, Laurence Zitvogel4, Guido Kroemer5.   

Abstract

Several pattern recognition receptors including toll-like receptors and purinergic receptors are implicated in the anticancer immune response elicited by anthracyclines or oxaliplatin. Recently, formyl peptide receptor-1 (FPR1) has been involved in this response as well. FPR1 is required for the correct positioning of dendritic cells (DC) close to dying cancer cells. A genetic defect in FPR1 abrogates cross-presentation of tumor antigens by DC, thereby compromising therapy-elicited immunosurveillance.

Entities:  

Keywords:  Annexin A1; CTL; DAMPs; apoptosis; immunogenic cell death

Year:  2016        PMID： 27467929      PMCID： PMC4910768          DOI： 10.1080/2162402X.2015.1118600

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Authors:  Erika Vacchelli; Yuting Ma; Elisa E Baracco; Antonella Sistigu; David P Enot; Federico Pietrocola; Heng Yang; Sandy Adjemian; Kariman Chaba; Michaela Semeraro; Michele Signore; Adele De Ninno; Valeria Lucarini; Francesca Peschiaroli; Luca Businaro; Annamaria Gerardino; Gwenola Manic; Thomas Ulas; Patrick Günther; Joachim L Schultze; Oliver Kepp; Gautier Stoll; Céline Lefebvre; Claire Mulot; Francesca Castoldi; Sylvie Rusakiewicz; Sylvain Ladoire; Lionel Apetoh; José Manuel Bravo-San Pedro; Monica Lucattelli; Cécile Delarasse; Valérie Boige; Michel Ducreux; Suzette Delaloge; Christophe Borg; Fabrice André; Giovanna Schiavoni; Ilio Vitale; Pierre Laurent-Puig; Fabrizio Mattei; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2015-10-29       Impact factor: 47.728

2.  An immunosurveillance mechanism controls cancer cell ploidy.

Authors:  Laura Senovilla; Ilio Vitale; Isabelle Martins; Maximilien Tailler; Claire Pailleret; Mickaël Michaud; Lorenzo Galluzzi; Sandy Adjemian; Oliver Kepp; Mireia Niso-Santano; Shensi Shen; Guillermo Mariño; Alfredo Criollo; Alice Boilève; Bastien Job; Sylvain Ladoire; François Ghiringhelli; Antonella Sistigu; Takahiro Yamazaki; Santiago Rello-Varona; Clara Locher; Vichnou Poirier-Colame; Monique Talbot; Alexander Valent; Francesco Berardinelli; Antonio Antoccia; Fabiola Ciccosanti; Gian Maria Fimia; Mauro Piacentini; Antonio Fueyo; Nicole L Messina; Ming Li; Christopher J Chan; Verena Sigl; Guillaume Pourcher; Christoph Ruckenstuhl; Didac Carmona-Gutierrez; Vladimir Lazar; Josef M Penninger; Frank Madeo; Carlos López-Otín; Mark J Smyth; Laurence Zitvogel; Maria Castedo; Guido Kroemer
Journal:  Science       Date:  2012-09-28       Impact factor: 47.728

Review 3.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

4.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Authors:  Yuting Ma; Sandy Adjemian; Stephen R Mattarollo; Takahiro Yamazaki; Laetitia Aymeric; Heng Yang; João Paulo Portela Catani; Dalil Hannani; Helene Duret; Kim Steegh; Isabelle Martins; Frederic Schlemmer; Mickaël Michaud; Oliver Kepp; Abdul Qader Sukkurwala; Laurie Menger; Erika Vacchelli; Nathalie Droin; Lorenzo Galluzzi; Roman Krzysiek; Siamon Gordon; Philip R Taylor; Peter Van Endert; Eric Solary; Mark J Smyth; Laurence Zitvogel; Guido Kroemer
Journal:  Immunity       Date:  2013-04-04       Impact factor: 31.745

Review 5.  Natural and therapy-induced immunosurveillance in breast cancer.

Authors:  Guido Kroemer; Laura Senovilla; Lorenzo Galluzzi; Fabrice André; Laurence Zitvogel
Journal:  Nat Med       Date:  2015-10       Impact factor: 53.440

Review 6.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

7.  Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.

Authors:  Gautier Stoll; David Enot; Bernhard Mlecnik; Jérôme Galon; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-02-27       Impact factor: 8.110

8.  An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.

Authors:  Mickaël Michaud; Xiaoqi Xie; José Manuel Bravo-San Pedro; Laurence Zitvogel; Eileen White; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

Review 9.  Trial Watch: Chemotherapy with immunogenic cell death inducers.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-03-01       Impact factor: 8.110

10.  Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set.

Authors:  Abdul Qader Sukkurwala; Sandy Adjemian; Laura Senovilla; Mickaël Michaud; Sabrina Spaggiari; Erika Vacchelli; Elisa Elena Baracco; Lorenzo Galluzzi; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2014-04-16       Impact factor: 8.110
  10 in total
  8 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

2.  Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways.

Authors:  Nella Prevete; Federica Liotti; Anna Illiano; Angela Amoresano; Piero Pucci; Amato de Paulis; Rosa Marina Melillo
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

3.  Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.

Authors:  Tao-Wei Ke; Shu-Fen Chiang; Kevin Chih-Yang Huang; William Tzu-Liang Chen; Tsung-Wei Chen; K S Clifford Chao
Journal:  Cancer Immunol Immunother       Date:  2021-03-13       Impact factor: 6.968

4.  Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer.

Authors:  Elisa E Baracco; Federico Pietrocola; Aitziber Buqué; Norma Bloy; Laura Senovilla; Laurence Zitvogel; Erika Vacchelli; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

5.  Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.

Authors:  Xue Jiang; Ting Lei; Man Zhang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

6.  Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2.

Authors:  Bin Ke; Ting Wei; Yuanyuan Huang; Yuxin Gong; Gang Wu; Junfang Liu; Xiaoting Chen; Lin Shi
Journal:  Mediators Inflamm       Date:  2019-12-14       Impact factor: 4.711

7.  A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Authors:  Julie Le Naour; Zsofia Sztupinszki; Vincent Carbonnier; Odile Casiraghi; Virginie Marty; Lorenzo Galluzzi; Zoltan Szallasi; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2022-04-17       Impact factor: 7.723

Review 8.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.